Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBITDA (2019 - 2023)

Historic EBITDA for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $2.7 billion.

  • ADC Therapeutics' EBITDA rose 8741535.0% to $2.7 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $2.7 billion, marking a year-over-year increase of 250722.19%. This contributed to the annual value of $4.3 billion for FY2022, which is 217896.54% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' EBITDA is $2.7 billion, which was up 8741535.0% from $2.5 billion recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' EBITDA ranged from a high of $4.3 billion in Q4 2022 and a low of -$70.7 million during Q1 2021
  • For the 5-year period, ADC Therapeutics' EBITDA averaged around $533.9 million, with its median value being -$3.1 million (2022).
  • As far as peak fluctuations go, ADC Therapeutics' EBITDA tumbled by 16102302863.17% in 2021, and later skyrocketed by 692257654.55% in 2022.
  • ADC Therapeutics' EBITDA (Quarter) stood at -$35732.0 in 2019, then tumbled by 146625.62% to -$52.4 million in 2020, then skyrocketed by 99.88% to -$62781.0 in 2021, then surged by 6922576.55% to $4.3 billion in 2022, then tumbled by 37.44% to $2.7 billion in 2023.
  • Its EBITDA was $2.7 billion in Q3 2023, compared to $2.5 billion in Q2 2023 and -$51.6 million in Q1 2023.